Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study

In conclusion, we found lower annualized rates o f MBE/CRNMBEs with dabigatran than VKA, although the difference was not statistically significant. Annualized rates of symptomatic VTE or related mortality were similar with dabigatran and VKA. These observational results with 1 year of follow-up reflect those of the randomized clinical trials. Trial registration: ClinicalTrials.gov identifier NCT02596230, first registered November 4, 2015.Graphic abstract
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research